Welcome to DZIF
It is the 21st century and infections are still a major challenge for medicine. What is our recourse as germs become increasingly resistant to antibiotics? What can we do to prevent the spread of a pathogen? The researchers at the German Center for Infection Research (DZIF) are tackling these and many other issues.
HIPS: A new building for pharmaceutical research
DZIF Chairman Martin Krönke and Rolf Müller, Director of the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), are pleased: The new HIPS building offers additional space for drug development. The Institute in Saarbrücken plays an important role in the development of new antibiotics at the German Center for Infection Research.
World Health Summit 2015
The six German Centres for Health Research (DZG), among them the German Center for Infection Research (DZIF), will also contribute their expertise to the World Health Summit: During the panel discussion “Education and training of clinical and translational scientists - different models in different countries".
In the DZIF, scientists prepare together with the company Hyglos clinical studies on an active substance against the dreaded hospital pathogen Staphylococcus aureus.
Fighting HIV with Antibodies
An international team of scientists, in collaboration with the DZIF, has now tested a new generation of antibodies in humans for the first time. They have demonstrated that these broadly neutralising antibodies significantly reduce the number of human immunodeficiency viruses (HIV) in infected patients’ blood.
11 September 2015 - PRESS RELEASE
Researchers at the Paul Ehrlich Institute (PEI) together with groups at the DZIF have developed a vaccine against MERS, that is highly immunogenic and indicates protection of vaccinated mice in challenge experiments. The data indicate that such recombinant measles viruses are suitable as a platform for developing vaccines against different emerging pathogens. [ more ]